Spruce Biosciences Common Stock Net Income
| SPRB Stock | USD 79.86 2.04 2.49% |
As of the 29th of January, Spruce Biosciences has the Risk Adjusted Performance of (0.05), coefficient of variation of (1,219), and Variance of 38.28. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spruce Biosciences Common, as well as the relationship between them.
Spruce Biosciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 112.3993 | Revenue | Earnings Share (84.32) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -47.7 M | -50.1 M | |
| Net Loss | -41.6 M | -43.6 M | |
| Net Loss | -47.7 M | -50.1 M | |
| Net Loss | (88.98) | (93.43) | |
| Net Income Per E B T | 0.91 | 0.81 |
Spruce | Net Income | Build AI portfolio with Spruce Stock |
Latest Spruce Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Spruce Biosciences Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Spruce Biosciences Common financial statement analysis. It represents the amount of money remaining after all of Spruce Biosciences Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Spruce Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spruce Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (53.04 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Spruce Net Income Regression Statistics
| Arithmetic Mean | (24,633,907) | |
| Coefficient Of Variation | (74.76) | |
| Mean Deviation | 16,985,891 | |
| Median | (9,858,000) | |
| Standard Deviation | 18,416,780 | |
| Sample Variance | 339.2T | |
| Range | 43.2M | |
| R-Value | (0.89) | |
| Mean Square Error | 76.3T | |
| R-Squared | 0.79 | |
| Slope | (3,239,983) | |
| Total Sum of Squares | 5426.8T |
Spruce Net Income History
Other Fundumenentals of Spruce Biosciences Common
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Spruce Biosciences Net Income component correlations
Spruce Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Spruce Biosciences is extremely important. It helps to project a fair market value of Spruce Stock properly, considering its historical fundamentals such as Net Income. Since Spruce Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spruce Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spruce Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Spruce Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (84.32) | Revenue Per Share | Quarterly Revenue Growth (0.76) | Return On Assets | Return On Equity |
Understanding Spruce Biosciences Common requires distinguishing between market price and book value, where the latter reflects Spruce's accounting equity. The concept of intrinsic value—what Spruce Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Spruce Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spruce Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Spruce Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Spruce Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Spruce Biosciences.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Spruce Biosciences on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Spruce Biosciences Common or generate 0.0% return on investment in Spruce Biosciences over 90 days. Spruce Biosciences is related to or competes with NRX Pharmaceuticals, Werewolf Therapeutics, OUTLOOK THERAPEUTICS, IO Biotech, Cue Biopharma, OS Therapies, and VTv Therapeutics. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rar... More
Spruce Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Spruce Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Spruce Biosciences Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 31.24 | |||
| Value At Risk | (9.46) | |||
| Potential Upside | 10.15 |
Spruce Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spruce Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Spruce Biosciences' standard deviation. In reality, there are many statistical measures that can use Spruce Biosciences historical prices to predict the future Spruce Biosciences' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (6.96) |
Spruce Biosciences January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (6.95) | |||
| Mean Deviation | 4.86 | |||
| Coefficient Of Variation | (1,219) | |||
| Standard Deviation | 6.19 | |||
| Variance | 38.28 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.52) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (6.96) | |||
| Maximum Drawdown | 31.24 | |||
| Value At Risk | (9.46) | |||
| Potential Upside | 10.15 | |||
| Skewness | 0.1814 | |||
| Kurtosis | 0.5036 |
Spruce Biosciences Common Backtested Returns
Spruce Biosciences Common owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0538, which indicates the firm had a -0.0538 % return per unit of risk over the last 3 months. Spruce Biosciences Common exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Spruce Biosciences' Coefficient Of Variation of (1,219), risk adjusted performance of (0.05), and Variance of 38.28 to confirm the risk estimate we provide. The entity has a beta of 0.0744, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Spruce Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Spruce Biosciences is expected to be smaller as well. At this point, Spruce Biosciences Common has a negative expected return of -0.33%. Please make sure to validate Spruce Biosciences' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Spruce Biosciences Common performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.19 |
Very weak predictability
Spruce Biosciences Common has very weak predictability. Overlapping area represents the amount of predictability between Spruce Biosciences time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Spruce Biosciences Common price movement. The serial correlation of 0.19 indicates that over 19.0% of current Spruce Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.19 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 17.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Spruce Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Spruce Biosciences Common reported net income of (53.04 Million). This is 115.54% lower than that of the Biotechnology sector and 175.72% lower than that of the Health Care industry. The net income for all United States stocks is 109.29% higher than that of the company.
Spruce Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spruce Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spruce Biosciences could also be used in its relative valuation, which is a method of valuing Spruce Biosciences by comparing valuation metrics of similar companies.Spruce Biosciences is currently under evaluation in net income category among its peers.
Spruce Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Spruce Biosciences from analyzing Spruce Biosciences' financial statements. These drivers represent accounts that assess Spruce Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spruce Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.1B | 203.2M | 50.3M | 110.0M | 126.5M | 120.2M | |
| Enterprise Value | 951.9M | 167.0M | 32.2M | 18.3M | 21.0M | 20.0M |
Spruce Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Spruce Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Spruce Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Spruce Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Spruce Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Spruce Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Spruce Biosciences' value.| Shares | Ubs Group Ag | 2024-12-31 | 86 K | Northern Trust Corp | 2024-12-31 | 80.3 K | Lion Point Capital, Lp | 2024-12-31 | 75 K | State Street Corp | 2024-12-31 | 60.7 K | Susquehanna International Group, Llp | 2024-12-31 | 59 K | Shay Capital Llc | 2024-12-31 | 38.1 K | Hrt Financial Llc | 2024-12-31 | 37.8 K | Xtx Topco Ltd | 2024-12-31 | 35.5 K | Bridgeway Capital Management, Llc | 2024-12-31 | 34.9 K | Rivervest Venture Management Llc | 2024-09-30 | 2.9 M | The Carlyle Group Inc | 2024-12-31 | 2.9 M |
Spruce Fundamentals
| Return On Equity | -1.68 | ||||
| Return On Asset | -0.77 | ||||
| Operating Margin | (71.00) % | ||||
| Current Valuation | 78.34 M | ||||
| Shares Outstanding | 1.07 M | ||||
| Shares Owned By Insiders | 9.11 % | ||||
| Shares Owned By Institutions | 41.06 % | ||||
| Number Of Shares Shorted | 61.19 K | ||||
| Price To Book | 16.28 X | ||||
| Price To Sales | 125.77 X | ||||
| Revenue | 4.91 M | ||||
| Gross Profit | (36.18 M) | ||||
| EBITDA | (52.68 M) | ||||
| Net Income | (53.04 M) | ||||
| Cash And Equivalents | 93.3 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 2.77 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.55 X | ||||
| Book Value Per Share | 9.56 X | ||||
| Cash Flow From Operations | (55.96 M) | ||||
| Short Ratio | 1.79 X | ||||
| Earnings Per Share | (84.32) X | ||||
| Target Price | 230.5 | ||||
| Beta | 3.63 | ||||
| Market Capitalization | 87.66 M | ||||
| Total Asset | 45.21 M | ||||
| Retained Earnings | (250.27 M) | ||||
| Working Capital | 28.96 M | ||||
| Net Asset | 45.21 M |
About Spruce Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spruce Biosciences Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spruce Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spruce Biosciences Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Common Stock:Check out Spruce Biosciences Piotroski F Score and Spruce Biosciences Altman Z Score analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Spruce Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (84.32) | Revenue Per Share | Quarterly Revenue Growth (0.76) | Return On Assets | Return On Equity |
Understanding Spruce Biosciences Common requires distinguishing between market price and book value, where the latter reflects Spruce's accounting equity. The concept of intrinsic value—what Spruce Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Spruce Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spruce Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.